samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

CPhI Worldwide: TE-ring remains firmly attached to the dropper bottle in line with FDA requirements

Gerresheimer AG

Niels Düring will be at booth 4.2 D02 at the CPhl, Frankfurt from October 24-26

Düsseldorf/Frankfurt, October 24, 2017 – It is often only minor improvements that make a product ideal to use. The TE-ring fixed to the type A eye-dropper bottle in accordance with the new FDA regulations is one good example.

"It’s often the technical details that add the finishing touches to packaging," says Niels Düring, Global Executive Vice President at Gerresheimer Plastic Packaging, who, with the help of his team, will showcase an extensive portfolio of plastic primary packaging for solids and liquids to existing and potential customers at booth 4.2 D02 at the CPhl in Frankfurt (Germany) from October 24-26.

TE-ring – now firmly attached to the bottle
The US Food and Drug Administration (FDA) now stipulate that the TE-ring must be firmly attached to the bottle. This product change was very easy to make, owing to experience with the type B dropper bottle, which already has a fixed TE-ring. Only minor adjustments were made to the design, while the dimensions, properties, and the materials are the same. The bottle and the dropper are made from LDPE and the cap from HDPE. The existing type A dropper bottles can therefore be used for stability tests.

Production of US dropper bottles with a fixed TE-ring will be operational in Q3, 2017 and production will besides Poland also be produced out of both India and US.

Gerresheimer produces type A dropper bottles holding 2-360 ml under clean-room conditions. Depending on the size of the container, they are produced using the injection blow molding (IBM) or the extrusion blow molding (EBM) process. Radiation or ETO sterilization is possible on request. All caps protect the original contents and can also be supplied with a child-proof screw cap.

You can find more information at www.gerresheimer.com

Plastic primary packaging for pharmaceuticals

About Gerresheimer
Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty glass and plastic products, the Company contributes to health and well-being. Gerresheimer operates worldwide and its approximately 10,000 employees manufacture products in local markets, close to its customers. With plants in Europe, North America, South America and Asia, Gerresheimer generates revenues of around EUR 1.4 bn. The company’s comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: insulin pens, inhalers, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Press Contact

Jens Kürten
Group Senior Director Communication & Marketing
Phone +49 211 6181-250
Fax +49 211 6181-241
E-mail j.kuerten@gerresheimer.com

Marion Stolzenwald
Senior Manager Corporate Communication
Phone +49 211 6181-246
Fax +49 211 6181-241
E-mail m.stolzenwald@gerresheimer.com
phone +49-(0)211/61 81-00
email info@gerresheimer.com
web www.gerresheimer.com
email Klaus-Bungert-Str. 4, 40468 Duesseldorf, Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CHDI Foundation extends collaboration with IRBM to accelerate development of Huntington’s disease therapeutics

IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
More info >>


White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

Industry Events

Drug Delivery Partnerships 2019

28-30 January 2019, PGA National Resort & Spa in Palm Beach Gardens, FL

For 23 years, DDP has been the world’s largest drug delivery meeting place to accelerate drugs to market and lengthen lifecycles for long term profitability by finding new partners, new drug delivery technologies, and new formulation development strategies. Year after year this event brings together top scientists and business development leaders from Biotech, Pharma, Generics, Specialty Pharma and Drug Delivery companies to share, discuss, and collaborate. If you work in drug delivery, commercialization/licensing, med device, formulation, biologics, biosimilars, and similar areas, you can’t miss this event!
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement